(Q33412191)

26 July 2017

Macrovascular involvement in a child with atypical hemolytic uremic syndrome (English)

1 reference

atypical hemolytic uremic syndrome

26 July 2017

1 reference

Michal Malina

3

0 references

author name string

Karolis Ažukaitis

1

1 reference

26 July 2017

Chantal Loirat

2

1 reference

26 July 2017

Irina Adomaitienė

4

1 reference

26 July 2017

Augustina Jankauskienė

5

1 reference

26 July 2017

19 December 2013

1 reference

26 July 2017

1 reference

26 July 2017

29

1 reference

26 July 2017

7

1 reference

26 July 2017

1273-1277

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-013-2713-3

26 July 2017

0 references

cites work

Atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Neurological involvement in a child with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Myocardial infarction is a complication of factor H-associated atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Moyamoya disease and moyamoya syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Peripheral gangrene in children with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Role of complement in the pathomechanism of atherosclerotic vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Moyamoya vasculopathy in a child after hemolytic uremic syndrome: a possible etiopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Profound neurological injury in a patient with atypical hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-013-2713-3

Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

21 January 2018

1 reference

12 December 2020

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

1 reference

12 December 2020

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases

1 reference

12 December 2020

Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab

1 reference

12 December 2020

10.1007/S00467-013-2713-3

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference